{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T13:10:03Z","timestamp":1765890603111,"version":"3.48.0"},"reference-count":57,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T00:00:00Z","timestamp":1698710400000},"content-version":"unspecified","delay-in-days":30,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100023331","name":"LEO Pharma","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100023331","id-type":"DOI","asserted-by":"crossref"}]},{"name":"CanVECTOR Network","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["CDT-142654"],"award-info":[{"award-number":["CDT-142654"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2023,9,11]]},"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The post-thrombotic syndrome (PTS) is a form of chronic venous insufficiency due to a prior ipsilateral deep venous thrombosis (DVT). This is a frequent complication that develops in 20%\u201350% of patients after a proximal DVT and is associated with significant healthcare, economic and societal consequences. In the absence of effective and well-tolerated treatment options for established PTS, effective preventative measures are needed. Anticoagulation itself reduces the risk of PTS, and low-molecular-weight heparin may reduce this further through anti-inflammatory properties targeting the initial acute inflammatory phase of DVT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>The Tinzaparin Lead-In to Prevent the Post-Thrombotic syndrome pilot trial is an investigator-initiated, multicentre, open-label assessor-blinded trial that will randomise patients with first acute symptomatic common femoral or iliac DVT to receive either a 3-week lead-in course of tinzaparin, followed by rivaroxaban (experimental arm) or rivaroxaban alone (control arm). Its primary objectives are to assess: (1) proportion of PTS at 6 months using the Villalta scale and (2) study feasibility, which consists of (a) the proportion of screened patients eligible for the study, (2) the proportion of eligible patients recruited and (c) the proportion of recruited patients adherent to treatment (defined as at least 80% of drug taken). This study will determine the feasibility of a subsequent larger definitive trial. Secondary outcomes include change of quality of life scores, PTS severity, global improvement, patient satisfaction, bleeding, recurrent venous thromboembolism, leg pain, death and lost to follow-up. Target recruitment will be a total of 60 participants, recruited at 5\u20136 centres.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Primary ethics approval was received from the Sunnybrook Health Sciences Center Research Ethics Board (approval ID 3315). Results of the study will be disseminated via peer-reviewed presentation at scientific conferences and open access publication.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04794569\">NCT04794569<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2022-064715","type":"journal-article","created":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T13:59:57Z","timestamp":1698760797000},"page":"e064715","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["TILE pilot trial study protocol: Tinzaparin Lead-in to Prevent the Post-Thrombotic syndrome study protocol"],"prefix":"10.1136","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct04794569","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9123-1271","authenticated-orcid":false,"given":"Ilia","family":"Makedonov","sequence":"first","affiliation":[{"name":"Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada"},{"name":"Department of Medicine, Southlake Regional Health Centre, Newmarket, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Kahn","sequence":"additional","affiliation":[{"name":"Department of Medicine, Jewish General Hospital, Montreal, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3648-2406","authenticated-orcid":false,"given":"Jameel","family":"Abdulrehman","sequence":"additional","affiliation":[{"name":"Department of Medicine, University Health Network, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8512-9043","authenticated-orcid":false,"given":"Sam","family":"Schulman","sequence":"additional","affiliation":[{"name":"Department of Medicine, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0227-1245","authenticated-orcid":false,"given":"Aurelien","family":"Delluc","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter L","family":"Gross","sequence":"additional","affiliation":[{"name":"Department of Medicine, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2705-3615","authenticated-orcid":false,"given":"Jean-Philippe","family":"Galanaud","sequence":"additional","affiliation":[{"name":"Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2023,10,31]]},"reference":[{"key":"2025121605053931000_13.10.e064715.1","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1055\/a-1711-1263","article-title":"Prevention of the postthrombotic syndrome with anticoagulation: a narrative review","volume":"122","author":"Makedonov","year":"2022","journal-title":"Thromb Haemost"},{"key":"2025121605053931000_13.10.e064715.2","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9040923","article-title":"Prevention and management of the post-thrombotic syndrome","volume":"9","author":"Makedonov","year":"2020","journal-title":"J Clin Med"},{"key":"2025121605053931000_13.10.e064715.3","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.thromres.2017.07.026","article-title":"Epidemiology of the post-thrombotic syndrome","volume":"164","author":"Galanaud","year":"2018","journal-title":"Thromb Res"},{"key":"2025121605053931000_13.10.e064715.4","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp110241"},{"key":"2025121605053931000_13.10.e064715.5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2011.04516.x"},{"key":"2025121605053931000_13.10.e064715.6","article-title":"Compression therapy for prevention of post-thrombotic syndrome","volume":"9","author":"Appelen","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2025121605053931000_13.10.e064715.7","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-1175"},{"key":"2025121605053931000_13.10.e064715.8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01333.x"},{"key":"2025121605053931000_13.10.e064715.9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2012.04872.x"},{"key":"2025121605053931000_13.10.e064715.10","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(46)91429-8","article-title":"Thrombosis early diagnosis and abortive treatment with heparin","volume":"1","author":"BAUER","year":"1946","journal-title":"Lancet"},{"key":"2025121605053931000_13.10.e064715.11","doi-asserted-by":"crossref","unstructured":"Galanaud J-P , Righini M , Qu\u00e9r\u00e9 I . Compression stockings to prevent post-thrombotic syndrome. Lancet 2014;384. doi:10.1016\/S0140-6736(14)61158-2","DOI":"10.1016\/S0140-6736(14)61158-2"},{"key":"2025121605053931000_13.10.e064715.12","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12127"},{"key":"2025121605053931000_13.10.e064715.13","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000130"},{"key":"2025121605053931000_13.10.e064715.14","doi-asserted-by":"publisher","DOI":"10.1160\/TH12-12-0931"},{"key":"2025121605053931000_13.10.e064715.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2011.02.033"},{"key":"2025121605053931000_13.10.e064715.16","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.surg.2019.05.030","article-title":"Comparison of the recanalization rate and postthrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin","volume":"166","author":"de Athayde Soares","year":"2019","journal-title":"Surgery"},{"key":"2025121605053931000_13.10.e064715.17","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1160\/TH16-01-0041","article-title":"Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin\/vitamin K antagonists for acute deep-vein thrombosis: a post-hoc analysis","volume":"116","author":"Cheung","year":"2016","journal-title":"Thromb Haemost"},{"key":"2025121605053931000_13.10.e064715.18","doi-asserted-by":"crossref","DOI":"10.1186\/2162-3619-3-30","article-title":"Comparative study of the effect of rivaroxaban and fondaparinux on monocyte\u2019s Coagulant activity and cytokine release","volume":"3","author":"Laurent","year":"2014","journal-title":"Exp Hematol Oncol"},{"key":"2025121605053931000_13.10.e064715.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2015.03.023"},{"key":"2025121605053931000_13.10.e064715.20","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/432080","article-title":"Evaluation of plaque stability of advanced atherosclerotic lesions in Apo E-deficient mice after treatment with the oral factor Xa inhibitor rivaroxaban","volume":"2011","author":"Zhou","year":"2011","journal-title":"Mediators Inflamm"},{"key":"2025121605053931000_13.10.e064715.21","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.carbpol.2016.12.037","article-title":"Non-anticoagulant effects of low molecular weight heparins in inflammatory disorders: a review","volume":"160","author":"Yan","year":"2017","journal-title":"Carbohydr Polym"},{"key":"2025121605053931000_13.10.e064715.22","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1684\/stv.2013.0807","article-title":"Non anticoagulant properties of heparin preparations: practical considerations","volume":"25","author":"Bal dit Sollier","year":"2013","journal-title":"Sang Thrombose Vaisseaux"},{"key":"2025121605053931000_13.10.e064715.23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1582-4934.2008.00658.x"},{"key":"2025121605053931000_13.10.e064715.24","doi-asserted-by":"publisher","DOI":"10.1016\/S0741-5214(98)70060-6"},{"key":"2025121605053931000_13.10.e064715.25","doi-asserted-by":"crossref","DOI":"10.3390\/ph9030038","article-title":"Heparin: past, present, and future","volume":"9","author":"Oduah","year":"2016","journal-title":"Pharmaceuticals (Basel)"},{"key":"2025121605053931000_13.10.e064715.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2007.11.040"},{"key":"2025121605053931000_13.10.e064715.27","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1002\/rth2.12120","article-title":"Comparison of antithrombin-dependent and direct inhibitors of factor Xa or thrombin on the Kinetics and qualitative characteristics of blood clots","volume":"2","author":"Salta","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"key":"2025121605053931000_13.10.e064715.28","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00160-7"},{"key":"2025121605053931000_13.10.e064715.29","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1160\/th15-04-0318","article-title":"Development and validation of a tool for patient reporting of symptoms and signs of the post-thrombotic syndrome","volume":"115","author":"Utne","year":"2016","journal-title":"Thromb Haemost"},{"key":"2025121605053931000_13.10.e064715.30","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2009.03294.x"},{"key":"2025121605053931000_13.10.e064715.31","unstructured":"Ware J , Kosinki M . SF-36 physical and mental summary measures: a user\u2019s manual. Boston: The Health Institute, New England Medical Center, 1994."},{"key":"2025121605053931000_13.10.e064715.32","doi-asserted-by":"publisher","DOI":"10.1067\/mva.2003.152"},{"key":"2025121605053931000_13.10.e064715.33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2702.2005.01121.x"},{"key":"2025121605053931000_13.10.e064715.34","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12301"},{"key":"2025121605053931000_13.10.e064715.35","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13140"},{"key":"2025121605053931000_13.10.e064715.36","unstructured":"Health Canada . Guidance document for industry - reporting adverse reactions to marketed health products: adverse reaction reporting by market authorization holders. 2013; 2018. 43. Available: http:\/\/hc-sc.gc.ca\/dhp-mps\/pubs\/medeff\/_guide\/2011-guidance-directrice_reporting-notification\/index-eng.php#a13 [Accessed 05 May 2021]."},{"key":"2025121605053931000_13.10.e064715.37","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1016\/S2352-3026(19)30209-1","article-title":"Ultrasound-accelerated catheter-directed thrombolysis versus anticoagulation for the prevention of post-thrombotic syndrome (CAVA): a single-blind, multicentre, randomised trial","volume":"7","author":"Notten","year":"2020","journal-title":"Lancet Haematol"},{"key":"2025121605053931000_13.10.e064715.38","doi-asserted-by":"publisher","DOI":"10.1177\/0962280215588241"},{"key":"2025121605053931000_13.10.e064715.39","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2288-13-104","article-title":"An audit of sample sizes for pilot and feasibility trials being undertaken in the United Kingdom registered in the United Kingdom clinical research network database","volume":"13","author":"Billingham","year":"2013","journal-title":"BMC Med Res Methodol"},{"key":"2025121605053931000_13.10.e064715.40","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61753-4"},{"key":"2025121605053931000_13.10.e064715.41","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1161\/CIRCULATIONAHA.118.037425","article-title":"Endovascular thrombus removal for acute Iliofemoral deep vein thrombosis: analysis from a stratified multicenter randomized trial","volume":"139","author":"Comerota","year":"2019","journal-title":"Circulation"},{"key":"2025121605053931000_13.10.e064715.42","doi-asserted-by":"crossref","unstructured":"Ware JE . SF-36 health survey: manual and interpretation guide. Health Assessment Lab; 2000.","DOI":"10.1097\/00007632-200012150-00008"},{"key":"2025121605053931000_13.10.e064715.43","unstructured":"Council CI of HRNS and ERC of C and SS and HR . Tri-council policy statement: ethical conduct for research involving humans. Ottawa Her Majesty the Queen in Right of Canada; 2018."},{"key":"2025121605053931000_13.10.e064715.44","unstructured":"ICMJE . Recommendations | defining the role of authors and contributors. Available: http:\/\/www.icmje.org\/recommendations\/browse\/roles-and-responsibilities\/defining-the-role-of-authors-and-contributors.html [Accessed 04 Feb 2022]."},{"key":"2025121605053931000_13.10.e064715.45","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1055\/s-0039-1677795","article-title":"Pharmacomechanical catheter-directed thrombolysis in acute femoral-popliteal deep vein thrombosis: analysis from a stratified randomized trial","volume":"119","author":"Kearon","year":"2019","journal-title":"Thromb Haemost"},{"key":"2025121605053931000_13.10.e064715.46","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.2165\/11203710-000000000-00000","article-title":"Tinzaparin sodium: a review of its use in the prevention and treatment of deep vein thrombosis and pulmonary embolism, and in the prevention of clotting in the extracorporeal circuit during haemodialysis","volume":"70","author":"Hoy","year":"2010","journal-title":"Drugs"},{"key":"2025121605053931000_13.10.e064715.47","unstructured":"Leo . Product monograph: Innohep. Thornhill; 2017. Available: https:\/\/www.leo-pharma.ca\/Files\/Filer\/LEOlocaldownloads\/LEO-Pharma.ca\/innohepPM(8.0)26-MAY-20171.pdf"},{"key":"2025121605053931000_13.10.e064715.48","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/jth.12814","article-title":"Inflammation markers and their trajectories after deep vein thrombosis in relation to risk of post-thrombotic syndrome","volume":"13","author":"Rabinovich","year":"2015","journal-title":"J Thromb Haemost"},{"key":"2025121605053931000_13.10.e064715.49","doi-asserted-by":"crossref","first-page":"106608","DOI":"10.1016\/j.vph.2019.106608","article-title":"Low prevalence of post-thrombotic syndrome in patients treated with rivaroxaban","volume":"124","author":"Ferreira","year":"2020","journal-title":"Vascular Pharmacology"},{"key":"2025121605053931000_13.10.e064715.50","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s11739-019-02215-z","article-title":"The risk of post-thrombotic syndrome in patients with proximal deep vein thrombosis treated with the direct oral anticoagulants","volume":"15","author":"Prandoni","year":"2020","journal-title":"Intern Emerg Med"},{"key":"2025121605053931000_13.10.e064715.51","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.thromres.2018.01.013","article-title":"Rivaroxaban versus warfarin for the prevention of post-thrombotic syndrome","volume":"163","author":"Utne","year":"2018","journal-title":"Thromb Res"},{"key":"2025121605053931000_13.10.e064715.52","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.thromres.2017.05.029","article-title":"Rivaroxaban versus warfarin in the prevention of post-thrombotic syndrome","volume":"157","author":"Jeraj","year":"2017","journal-title":"Thromb Res"},{"key":"2025121605053931000_13.10.e064715.53","article-title":"Post-thrombotic syndrome in patients with venous thromboembolism treated with Dabigatran or warfarin - a long-term cross-sectional follow-up of RE-COVER study patients","volume":"4:Abstract P","author":"Wik","year":"2020","journal-title":"Res Pr Thromb Haemost"},{"key":"2025121605053931000_13.10.e064715.54","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1177\/1076029618758955","article-title":"Postthrombotic syndrome in patients treated with rivaroxaban or warfarin for venous thromboembolism","volume":"24","author":"Coleman","year":"2018","journal-title":"Clin Appl Thromb Hemost"},{"key":"2025121605053931000_13.10.e064715.55","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.amjmed.2018.01.041","article-title":"Rivaroxaban versus warfarin and risk of post-thrombotic syndrome among patients with venous thromboembolism","volume":"131","author":"S\u00f8gaard","year":"2018","journal-title":"Am J Med"},{"key":"2025121605053931000_13.10.e064715.56","doi-asserted-by":"publisher","DOI":"10.1160\/TH13-09-0803"},{"key":"2025121605053931000_13.10.e064715.57","article-title":"Vitamin K antagonists versus low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism","volume":"7","author":"Andras","year":"2017","journal-title":"Cochrane Database Syst Rev"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2022-064715","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T13:05:52Z","timestamp":1765890352000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2022-064715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":57,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,10,31]]},"published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1136\/bmjopen-2022-064715"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2022-064715","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2023,10]]}}}